Latest News and Press Releases

New Drug Application (NDA) for relugolix monotherapy tablet in advanced prostate cancer accepted for Priority Review by the FDA with target action date of December 20, 2020NDA for relugolix...

USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma to further support planned commercialization of relugolix across multiple indicationsAgreement with Sunovion...

Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic womenDetailed data from ovulation inhibition study demonstrate...

Forward Momentum brings together healthcare, research, and advocacy organizationsInitial projects focus on increasing diversity in COVID-19 research and developing digital resources to support the...

Co-primary endpoints met with response rates of 74.5% for dysmenorrhea (menstrual pain) and 58.5% for non-menstrual pelvic pain (p-values < 0.0001)Women receiving relugolix combination therapy, on...

BASEL, Switzerland, June 22, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will host a...

Priority Review status expected to accelerate review, with a target FDA action date of December 20, 2020 BASEL, Switzerland, June 22, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a...

NDA is supported by positive data from two Phase 3 studies and a long-term extension study, demonstrating sustained reduction in heavy menstrual bleeding while maintaining bone health through one...

Phase 3 data presented in oral presentation during the ASCO20 Virtual Scientific Program, with simultaneous publication in the New England Journal of MedicinePresentation expands on previous results...

- Co-primary endpoints and six key secondary endpoints met in Phase 3 SPIRIT 2 study in women with endometriosis, with results from the Phase 3 SPIRIT 1 study expected in the second quarter of...